In a report released today, Michael Wiederhorn from Oppenheimer maintained a Hold rating on CVS Health (CVS). The company’s shares closed last Monday at $73.85, close to its 52-week high of $77.03.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 17.2% and a 71.9% success rate. Wiederhorn covers the Services sector, focusing on stocks such as The Ensign Group, Addus Homecare, and UnitedHealth.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CVS Health with a $87.71 average price target.
See today’s analyst top recommended stocks >>
Based on CVS Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $64.81 billion and net profit of $1.53 billion. In comparison, last year the company earned revenue of $54.42 billion and had a GAAP net loss of $419 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CVS Health Corp. engages in the provision of health care services. It operates trough the following segments: Pharmacy Services, Retail or Long Term Care, Health Care Benefits and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions.